Results 201 to 210 of about 2,450,308 (424)
Molecular Oncology, Volume 19, Issue 5, Page 1299-1309, May 2025.Transient receptor potential melastatin‐4 (TRPM4) is overexpressed in prostate cancer (PCa). Knockout of TRPM4 resulted in reduced PCa tumor spheroid size and decreased PCa tumor spheroid outgrowth. In addition, lack of TRPM4 increased cell death in PCa tumor spheroids.
Florian Bochen +6 more
wiley +1 more source
Point-of-Care Testing. Christopher P. Price, PhD, FRCPath, and Jocelyn M. Hicks, PhD, FRCPath, eds. Washington, DC: AACC Press, 1999, 580 pp., $79.00. ISBN 1-890883-23-9. [PDF]
, 2001 Jan Lindemans
openalex +1 more source
Background: Hepatitis C (HCV) testing innovations such as dried blood spot (DBS) and point-of-care testing should have fewer client-related barriers than traditional diagnostic pathways, yet there is limited evidence on their acceptability among people ...
Cunningham, EB +6 more
core +1 more source
Molecular Oncology, Volume 19, Issue 5, Page 1452-1470, May 2025.Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti +8 more
wiley +1 more source
AnimalsViscoelastic monitoring of horse coagulation is increasing due to its advantages over traditional coagulation testing. The use of a point-of-care viscoelastic coagulation monitor (VCM Vet™) has been validated for use in horses using native whole blood ...
Jessica R. Vokes +5 more
doaj +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
Molecular Oncology, EarlyView.mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia +17 more
wiley +1 more source
Reducing Potential Medical Errors in Point-of-Care Testing [PDF]
, 2002 Gerald J. Kost +5 more
openalex +1 more source
Point-of-care testing management – benefits and pitfalls [PDF]
, 2014 Point-of-care testing (POCT) or near-patient testing conducted outside of the laboratory by clinical staff is the fastest growing segment of laboratory diagnostics worldwide.
DUNJA ROGIĆ
core +1 more source